Age-Related Macular Degeneration

The use of bevacizumab has allowed patients to receive adequate care for various retinal diseases including wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema and macular edema due to retinal vein occlusions.

During the COVID slowdown, researchers seem to have sped up publishing breakthrough research on age-related macular degeneration. Much of this can be applied to real-life optometric practice.

As COVID-19 ushered telemedicine and virtual visits to the forefront of clinical practice, artificial intelligence has emerged as an important way to augment care.

Age-related macular degeneration is one of the leading causes of vision loss in the elderly population. Although new treatments have been beneficial in reducing vision loss and slowing the disease, they often come with a difficult burden.

Iveric bio received a special protocol assessment from the FDA for GATHER2, a pivotal clinical trial investigating Zimura in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses treating patients in real-world clinical practice, with a focus on vitamin therapy to prevent progression in dry AMD and a treat-and-extend approach for wet AMD.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institue, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses how many patients failed to adhere to follow-up recommendations and continue anti-VEGF therapy over the COVID-19 pandemic and studies he has conducted that detail the negative outcomes of missing follow-up.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses exploring gene therapy in intermediate and advanced stages of dry AMD.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses medication delivery options, such as port delivery system and using antibiotic prophylaxis.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses Highlights from ARVO 2021 in AMD, including 10-year data from The Age-Related Eye Disease Study 2 (AREDS2), APL-2 for geographic atrophy, clinical practice data on brolucizumab (Beovu, Novartis) and more.